Oral Controlled Release-Based Products for Life Cycle Management

Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice

Volumn , Issue , 2010, Pages 305-320

  Davar, Nipun ^a   Ghosh, Sangita ^a  

^a Transcept Pharmaceuticals Inc   (United States)

Author keywords

Controlled release formulation, Coreg CR simplifying treatment regimen and improved compliance for patients with heart disease; in vitro in vivo correlation (IVIVC) justifying release rate specifications of CR dosage form; Oral controlled release based products for life cycle management

Indexed keywords

EID: 84880410615     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470640487.ch18     Document Type: Chapter

References (69)

1. Available at http://drugtopics.modernmedicine.com/drugtopics/ Supplements/Drug-patent-expirations-2007-2009/ArticleStandard/ Article/detail/414709.
2. Reformulation strategies: comparisons of past and future reformulation strategies. Available at http://www.datamonitor. com. Accessed Sept 2006.
3. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K,Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin. Pharmacokinet. 2001;40:411-426.
4. Andersson T, Rohss K, Bredberg E, Hassan-Alin M. Pharmacokinetics and pharmacodynamics of esomeprazole, the Sisomer of omeprazole. Aliment. Pharmacol. Ther. 2001;15: 1563-1569.
5. Lind T, Rydberg L, Kyleback A, Jonsson T, Hasselgren G, Holmberg J, Rohss K. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 2000;14:861-867.
6. Grant JA, Danielson L, Rihoux J-P, DeVos C. A comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo in suppressing the cutaneous response to histamine. Int. Arch. Allergy Immunol. 1999; 118:339-340.
7. Available at http://www.gsk.com/investors/product_pipeline/ docs/gsk-pipeline-feb08.pdf.
8. Modi N, Gupta SK. Development of controlled release products. In Bonate PL, Howard DR, editors. Pharmacokinetics in Drug Development: Regulatory and Development Paradigms, Vol. 2, AAPS Press, Arlington, VA, 2004, pp. 343-358.
9. Yacobi A, Halperin-Walega E. Oral Sustained Release Formulations, Design and Evaluation, Pergamon, New York, 1988.
10. Wong PSL, Gupta SK, Stewart BE. Osmotically controlled tablets. In Rathbone MJ, Hadgraft J, Roberts MS, editors. Modified Release Drug Delivery Technology, Marcel Dekker, New York, 2003, pp. 101-114.
11. Swanson JM, Wigal SB, Udrea D, Lerner M, Agler D, Flynn D, Fineberg E, Davies M, Kardatzke D, Ram A, Gupta S. Evaluation of individual subjects in the analog classroom setting: I. Examples of graphical and statistical procedures for within-subject ranking of responses to different delivery patterns of methylphenidate. Psychopharmacol. Bull. 1998; 34:825-832.
12. Swanson J, Gupta S, Guinta D, Flynn D, Agler D, Lerner M, Williams L, Shoulson I, Wigal S. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin. Pharmacol. Ther. 1999;66: 295-305.
13. Guidance for Industry. Application covered by Section 505(b)(2), Food and Drug Administration, CDER, October 1999.
14. Furrow ME. Pharmaceutical patent life-cycle management after KSR v. Teleflex. Food Drug Law J. 2008;63:275-320.
15. Nicolaou S. Regulatory and intellectual property issues in drug delivery research. InWang B, Siahaan TJ, Soltero RA, editors. Drug Delivery Principles and Application, JohnWiley& Sons, Inc., New Jersey, 2005, pp. 435-442.
16. US Patent Application 2005/0208132.
17. Available at http://www.drugpatentwatch.com.
18. Wargin W, Patrick K, Kilts C, Gualtieri CT, Ellington K, Mueller RA, Kraeme G, Breese GR. Pharmacokinetics of methylphenidate in man, rat and monkey. J. Pharmacol. Exp. Ther. 1983;226:382-386.
19. Patrick KS, Mueller RA, Gualtieri CT, Breese GR. Psychopharmacology: The Third Generation of Progress, Raven, New York, 1987, pp. 1387-1395.
20. Modi NB, Lindemulder B, Gupta SK. Single and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlledrelease OROS (methylphenidate HCl) formulation. J. Clin. Pharmacol. 2000;40:379-388.
21. Pelham WE, Gnagy EM, Burrows-Mclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fiebelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001;107-105.
22. Concerta® [package insert], ALZA Corporation, Mountain View, CA, 2007.
23. Spencer TJ, Biederman J, Ciccone PE, Madras BK, Dougherty DD, Bonab AA, Livni E, ParasrampuriaDA, Fischman AJ. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am. J. Psychiatry 2006; 163:387-395.
24. Lam AC, Shivanand P, Ayer AD, Hatamkhany Z, Gupta SK, Guinta DR, Christopher CA, Saks SR, Hamel LG, Wright JD, Weyers RG,inventors, Alza Corporation, assignee. Methods and devices for providing prolonged drug therapy. US Patent 6,930,129, 2005 Aug 16.
25. Lam AC, Shivanand P,Ayer AD,Weyers RG, Gupta SK, Guinta DR, Christopher CA, Saks SR, Hamel LG, Wright JD, Hatamkhany Z,inventors, Alza Corporation, assignee. Methods and devices for providing prolonged drug therapy. US Patent 6,919,373, 2005 July 19.
26. Doyle BB, Understanding and Treating Adults with Attention Deficit Hyperactivity Disorder, American Psychiatric Publishing, 2006.
27. Srinivas NR, Hubbard JW, Quinn D, Midha KK. Enantioselective pharmacokinetics and pharmacodynamics of DL-threomethylphenidate in children with attention deficit hyperactivity disorder. Clin. Pharmacol. Ther. 1992;52:561-568.
28. Spencer T, Biederman J,WilensT, Doyle R, Surman C, Prince J, Mick E, Aleardi M, Herzig K, Faraone S. A large, double-blind randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol. Psychiatry 2005;57:156-163.
29. Mehta AM, Zeitlin AL, Dariani MM,inventors, Celegene Corporation, assignee. Delivery of multiple doses of medications. US Patent 5,837,284, 1998 Nov 17.
30. Mehta AM, Zeitlin AL, Dariani MM,inventors, Celegene Corporation, assignee. Delivery of multiple doses of medications. US Patent 6,635,284, 2003 Oct 21.
31. Devane JG, Stark P, Fanning NMM,inventors, Elan Corporation, plc, assignee. Multiparticulate modified release composition. US Patent 6,730,325, 2004.
32. Mehta AM, Zeitlin AL, Dariani MM,inventors, Celegene Corporation, assignee. Delivery of multiple doses of medications. US Patent 6,635,284, 2003 Oct 21.
33. Focalin® XR [package insert], Novartis Pharmaceuticals Corporation, East Hanovar, NJ, 2006 Label information.
34. Gonzalez MA, Pentikis HS, Anderi N, Benedict MF, DeCory HH, Hirshey Dirksen SJ, Hatch SJ. Methylphenidate bioavailability from two extended-release formulations. Int. J. Clin. Pharmacol. Ther. 2002;40(4):175-184.
35. US Patent 5,968,552, 1999 Oct 19.
36. Verma R, Garg S. Current status of drug delivery technologies and future directions. Pharma. Technol. 2001;25(2):1-14.
37. Prisant LM, Elliott WJ. Drug delivery systems for treatment of systemic hypertension. Clin. Pharmacokinet. 2003;42(11): 931-940.
38. Felicetta JV, Serfer HM, Cutler NR, Comstock TJ, Huber GL, Weir MR, Hafner K, Park GD. A dose-response trial of oncedaily diltiazem. Am. Heart J. 1992;123(4 Pt 1):1022-1026.
39. Hendrickson DL, Dimmitt DC, Williams MS, Skultety PF, Baltezor MJ,inventors, Carderm Capital L.P., assignee. Diltiazem formulation. US Patent 5,286,497, 1994 Feb 15.
40. Hendrickson DL, Dimmitt DC, Williams MS, Skultety PF, Baltezor MJ,inventors, Carderm Capital L.P., assignee. Diltiazem formulation. US Patent 5,470,584, 1995 Nov 28.
41. Page RL. Evolving concepts in chronotherapy with CCBs: implications for pharmacists. Available at https://secure.pharmacytimes. com/lessons/200503-03.asp. Accessed 2005.
42. Cardizem LA [package insert], Biovail Pharmaceuticals, Bridgewater, NJ, April 2004.
43. Sista S, Lai JC, Eradiri O, Albert KS. Pharmacokinetics of a novel diltiazem HCl extended-release tablet formulation for evening administration. J. Clin. Pharmacol. 2003;43: 1149-1157.
44. Thiffault J, Landriault H, Gossard D, Raymond M, Caille G, Spenard J. The influence of time of administration on the pharmacokinetics of a once-a-day diltiazem formulation: morning against bedtime. Biopharm. Drug Dispos. 1996; 17:107-115.
45. Glasser SP, Neutel JM, Gana TJ, Albert KS. Efficacy and safety of a once daily graded-release diltiazem formulation in essential hypertension. Am. J. Hypertens. 2003;16:51-58.
46. Albert KS, Maes PJ,inventors, Biovail Laboratories International SRL, assignee. Chronotherapeutic diltiazem formulations and the administration thereof. US Patent 7,108,866, 2006 Sept 19.
47. Remon JP, inventor, Universiteit Gent, assignee. Cushioning wax beads for making solid shaped articles. US Patent 6,923,984, 2005 Aug 2.
48. Agarwal N, Thakkar N. Surviving patent expiration: strategies for marketing pharmaceutical products. J. Product Brand Manage. 1997;6(5):305-314.
49. Conte U, La Manna A, Colombo P,inventors, Jagotec AG, assignee. Tablets with controlled-rate release of active substances. US Patent 5,422,123, 1995 June 6.
50. Frishman WH. A new extended-release formulation of diltiazem HCI for the treatment of mild-to-moderate hypertension. J. Clin. Pharmacol. 1993;33:612-622.
51. Procardia® XL [package insert], Pfizer Inc., New York, NY, 2003 Label information.
52. Mohiuddin SM, Lucas BD Jr, Shinn B, Elsasser GN. Conversion from sustained-release to immediate-release calcium entry blockers: outcome in patients with mild-to-moderate hypertension. Clin. Ther. 1993;15(6):1002-1010.
53. Brodgen RN, McTavish D. Nifedipine gastrointestinal therapeutic system (GITS): a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris. Drugs 1995;50: 495-512.
54. Kleinbloesem CH, Van Brummelen P. Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin. Pharmacol. Ther. 1987;41:26-30.
55. Available at http://www.gsk.com/media/pressreleases/2006/ 2006_05_17_GSK833.htm.
56. Henderson LS, Tenero DM, Baidoo CA, Campanile AM, Hatter AH, Boyle D, Danoff TM. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. Am. J. Cardiol. 2006;98(7A): 17L-26L.
57. WeberMA, SicaDA,Tarka EA, Iyengar M, Fleck R, Bakris GL, Coreg 367 Investigator Group. Once-daily carvedilol is effective in treating hypertension. Presented at the American College of Cardiology Annual Meeting, 2006.
58. Autant P, Selles JP, Soula G,inventors, Flamel Technologies, assignee. Medicinal and/or nutritional microcapsules for oral administration. US Patent 6,022,562, 2000 Feb 8.
59. Available at http://clinicaltrials.gov.
60. Mcguire S. AstraZeneca seeks new Seroquel XR indications. Available at http://www.mmm-online.com/AstraZeneca-seeksnew- Seroquel-XR-indications/article/100315. Accessed 2008.
61. Seroquel® XR [package insert], AstraZeneca Pharmaceuticals LP, Wilmington, DE, 2007 Label information.
62. Parikh BV, Timco RJ, Addiks WJ,inventors, Zeneca Limited, assignee. Pharmaceutical compositions using thiazepine. US Patent 5,948,437, 1999 Sept 7.
63. Available at http://www.astrazeneca.com/pressrelease/5379.aspx.
64. Gupta SK, Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J. Clin. Pharm. 1999;39:22-29.
65. Sathyan G, Chancellor MB, Gupta SK. Effect of OROS controlled release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br. J. Clin. Pharmacol. 2001;52(4):409-417.
66. Anderson RU, Mobley D, Blank D, Saltzstein D, Susset J, Brown JS. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J. Urol. 1999;161:1809-1812.
67. Lindeke B, Hallströom G, Johansson C, Ericsson K, Olsson LI, Ströomberg S. Metabolism of oxybutnin: establishment of desethyloxybutynin and oxybutyninN-oxide formation in rat liver preparations using deuterium substitution and gas chromatographic mass spectrometric analysis. Biomed. Mass Spec. 1981;8:506-513.
68. Aaltonen L, Allonen H, Lisalo E, Juhakoski A, Kleimola T, Sellman R. Antimuscarinic activity of oxybutynin in the human plasma quantitated by a radioreceptor assay. Acta Pharmacol. Toxicol. 1998;55:100-103.
69. Madersbacher H, Jilig G. Control of detrusor hyperflexia by the intravesical instillation of oxybutynin hydrochloride. Paraplegia 1991;29:84-90.